Using focused ultrasound to treat allergic rhinitis
Prospective Multicenter Observational Study and Promotion of the Application of Focused Ultrasound in "Reduction of Hypertrophy" and "Desensitization" for Allergic Rhinitis
This study is testing if a new non-invasive ultrasound treatment can help people with stubborn allergic rhinitis feel better by reducing symptoms like nasal congestion and sneezing.
Quick facts
| Phase | Early Phase 1 |
|---|---|
| Study type | Interventional |
| Enrollment | 240 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Chongqing Medical University Academic / other |
| Locations | 1 site (Chongqing, Chongqing) |
| Trial ID | NCT06272032 on ClinicalTrials.gov |
What this trial studies
This study investigates the use of high-intensity focused ultrasound (HIFU) as a non-invasive treatment for patients with refractory allergic rhinitis. It aims to assess the clinical efficacy and safety of HIFU in alleviating symptoms associated with allergic rhinitis, such as nasal congestion and sneezing. The study will be conducted across multiple centers, collaborating with six established institutions that specialize in ultrasound treatments. Participants will also receive standard medications like intranasal corticosteroids and antihistamines as part of their treatment regimen.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 70 with refractory allergic rhinitis who experience persistent symptoms despite standard treatments.
Not a fit: Patients with uncontrolled asthma, severe cardiovascular diseases, or those under 18 or over 70 years of age may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could provide a new, effective treatment option for patients suffering from persistent allergic rhinitis.
How similar studies have performed: While focused ultrasound is a novel approach in treating allergic rhinitis, preliminary studies have shown promising results, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Refractory AR. 2. Patients exhibiting persistent mucosal hypersensitivity or high secretion state (rhinorrhea, sneezing, etc.). Exclusion Criteria: 1. Patients with exacerbation of nasal symptoms, uncontrolled or acute exacerbation of asthma 2. Patients with bleeding tendency, coagulation disorders 3. Patients with poor overall condition, unable to tolerate procedures 4. Patients with severe cardiovascular diseases, immune system disorders, malignant tumors 5. Patients with psychological disorders or poor compliance, combined with primary immunological diseases (such as Sjögren's syndrome) or abnormal results of tear secretion tests, etc. 6. Patients under 18 years of age or over 70 years of age
Where this trial is running
Chongqing, Chongqing
- Chongqing Medical University — Chongqing, Chongqing, China (Recruiting)
Study contacts
- Study coordinator: Shen Yang, Doctoral
- Email: sy_smile@sina.cn
- Phone: 15111953398
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.